PON2 and leukemia: Previous studies linked PON2 with several diseases including leukemia (see [26] and references therein) and showed that CML-like K562 cells obviously required PON2 for both survival and resistance against the CML chemotherapeutic Imatinib Mesylate (STI-571) [25].